Drugs take the high-quality and low-cost route under the base medicine system

It is understood that China's basic medicine list has been continuously updated and has reached more than 300 kinds. Together with a variety of medical insurance products, basic drugs have covered the basic drugs for the people.

According to the China Merchants Investment Network, in the context of the implementation of the basic drug system, if pharmaceutical companies can find the best balance between price and quality, it means seizing a market opportunity.

Under the background of “oil price rises and drug prices falling”, examples of bidding prices for base medicines bidding far below the normal production cost continue to emerge. This raises people's concerns about the quality and safety of such successful drugs, and also allows people to re-examine the definition of what is the "cheapest drug," and domestic pharmaceutical companies have repeatedly vocal "survival difficulties."

"As long as pharmaceutical companies focus on quality and efficacy, profits will continue to flow." In the view of pharmaceutical agents, the phrase that European drugmaker Bayer said more than 100 years ago is the biggest spur to current pharmaceutical companies. .

However, at the salon of the China Pharmaceutical Alliance held in Chengdu on April 19, many experts believed that in the market dominated by the government, drugs are cheap and high quality, which is the general trend. If pharmaceutical companies can find low prices, And ensuring the best balance of quality means seizing another market opportunity.

Understand the nature of the industry, “The momentum of rising drug costs is irreversible, and the government’s determination to advance the drug-based system is irreversible. The decline in drug prices is irreversible.” Wu Qinggong, vice president of the Chinese Pharmaceutical Enterprise Management Association, believes that this is the current domestic pharmaceutical companies are facing The industry environment.

The extent to which pharmaceutical companies meet this demand will be the key to the success of pharmaceutical companies in seizing this market. However, from the earlier occasions when the bid price of the base drug was far lower than the production cost, some pharmaceutical companies have already experienced “bias” in the government’s desire for pharmaceutical companies to provide quality and cheap drugs.

The drug-based market is mainly government-oriented. Therefore, pharmaceutical companies undoubtedly need to study in depth and meet the needs of the government. From the series of policies introduced by the government, it seems obvious that its intention to require pharmaceutical companies to provide ordinary people with cheap and high-quality drugs is obvious.

With regard to the consequences of this "deviation," Yao Fucan, chairman of the Good Medical Group, believes that it is tantamount to the shame of the pharmaceutical industry. It is understood that some compound Danshen tablets, Niuhuangjiedu tablets, Banlangen particles and other products currently on the market are sold, but if they are manufactured according to the process standards, their cost will be higher than the market price. The cost of raw materials for compound Danshen tablets will not be lower than 4.5 yuan, but the market price is only 0.5-0.6 yuan.

In the opinion of some industry experts, basic pharmaceutical manufacturers have not been able to study the needs of the government in depth and to meet the government's desire to provide quality and cheap medicines for the people. To a certain extent, it is due to the fact that some companies are not profound about the nature of the pharmaceutical industry. Understanding leads to.

Yan Fu Neng pointed out that the essence of the pharmaceutical industry does not lie in the technology, funds, and product prices, but in ensuring the safety and efficacy of drugs.

With the in-depth promotion of the basic system, the number of basic drug market will be more and more, and the prospect of the base drug market is optimistic. The company hopes to have some compensation mechanisms in the bidding for base medicines so as to stimulate the enthusiasm of the enterprises. Only pharmaceutical companies face and internalize the essence of this industry, so as to ensure that the quality of drugs can no longer be reduced to empty talk, and the supply of quality and cheap basic drugs can become possible.